| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Myriad Genetics (NASDAQ:MYGN) is gearing up to announce its quarterly earnings on Tuesday, 2025-08-05. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Myriad Genetics will report an earnings per share (EPS) of $-0.05.
Investors in Myriad Genetics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
In the previous earnings release, the company beat EPS by $0.02, leading to a 41.27% drop in the share price the following trading session.
Here's a look at Myriad Genetics's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.05 | 0.03 | 0.02 | -0.01 |
| EPS Actual | -0.03 | 0.03 | 0.06 | 0.05 |
| Price Change % | -41.0% | -15.0% | -1.0% | 3.0% |
Shares of Myriad Genetics were trading at $3.91 as of August 01. Over the last 52-week period, shares are down 84.77%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for Myriad Genetics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MYGN
